AstraZeneca’s Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation
- Posted on January 19, 2025
- By Financial Express
- 2 Views
AstraZeneca’s Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for 50% of the company’s total revenue by 2030.
